Although substantial research efforts have been invested into the utilization of glutamine and glutamate in cancer, a study led by Ying Xu reports for the first time on comparative analyses of glutamine and glutamate metabolisms across 11 cancer types by using gene-expression data of cancer vs. control tissues. As shown in the cover art, by using fixed effect model, this study estimated level of statistical contribution from glutamine/glutamate and/or their up-stream pathways in each cancer type (perimeter axis) to metabolic processes (radius axis) including: purine synthesis, pyrimidine synthesis), energy synthesis, lipid synthesis, nucleotide synthesis, UDP-GlcNAc synthesis, asparagine synthesis, proline synthesis, serine synthesis, and GSH synthesis. This study suggested: (1) glutamine generally does not contribute to purine synthesis in cancer except for BRCA, similar not to pyridine synthesis except for KIRC; (2) glutamine generally does not contribute to ATP production in cancer; (3) the contribution to general nucleotide synthesis by glutamine is minimal if any in cancer; (4) glutamine does not contribute to asparagine synthesis in cancer except BLCA and LUAD; and (5) glutamate generally does not contribute to serine synthesis except for BLCA; and (iv) strong correlations between increased glutamine and glutamate metabolisms and increased ROS level Induce an anti-oxidation function of glutamine and glutamate. For more details, please read the article on pages 712-725 of this CJC issue. (The cover art is provided by Dr. Sha Cao and colleagues.)